Strengths

Negative cash conversion cycle of -184 days materially outperforms most consumer-health peers, because supplier financing supports working-capital efficiency and cash retention.

ROIC of 6.5% indicates modest value creation, but it remains structurally better than many large-cap packaged-health peers that still earn near or below capital costs.

The portfolio’s scale in consumer health and OTC categories supports shelf access and brand reach versus smaller peers, which helps defend demand stability across cycles.

Lower capital intensity than pharma peers improves operating flexibility, because the business can sustain investment without the same R&D burden or patent-expiry volatility.

Weaknesses

Net debt to EBITDA of 2.6x leaves leverage elevated versus stronger consumer-health peers, which constrains financial flexibility if margins or volumes soften.

Current ratio of 0.69 and quick ratio of 0.52 indicate weak short-term liquidity, making the balance sheet less resilient than peers with stronger working-capital buffers.

ROIC remains only mid-single-digit, so the company trails higher-quality healthcare peers that compound capital at materially higher rates over time.

The absence of disclosed margin metrics limits evidence of operating efficiency, but the available leverage and liquidity profile still point to weaker financial positioning than top peers.

Opportunities

Further working-capital optimization could extend the already negative cash conversion cycle, which would widen the gap versus peers with slower inventory and receivables turns.

If management improves leverage, the company could narrow the valuation and risk discount versus stronger balance-sheet peers, supporting more durable capital allocation.

Consumer-health demand is typically resilient, so incremental share gains in OTC and self-care categories could compound faster than in more cyclical healthcare segments.

Portfolio simplification and brand investment can improve mix quality over time, which would help HLN close the profitability gap with better-positioned peers.

Threats

High leverage increases sensitivity to refinancing costs and earnings volatility, leaving HLN more exposed than peers with stronger balance sheets in a higher-rate environment.

Weak liquidity raises execution risk if working capital tightens, because peers with larger cash buffers can absorb shocks more easily.

Consumer-health competition from larger global branded players can pressure pricing and shelf space, limiting HLN’s ability to defend margins versus scale leaders.

If ROIC stays near mid-single digits, HLN risks lagging peers that reinvest at higher returns, which would keep relative positioning structurally weaker over time.

Overall Score

HLN shows some structural cash-efficiency strengths, but leverage and liquidity remain weaker than stronger consumer-health peers, keeping overall positioning moderate.